Gravity Analytica

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

CRNX 01.06.2025

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-14

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our CRNX Tweets

About Gravity Analytica

Recent Filings

SAN DIEGO,Jan. 06, 2025(GLOBE NEWSWIRE) --Crinetics Pharmaceuticals, Inc.(Nasdaq: CRNX) today announced thatScott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 43^rdAnnualJ.P. Morgan Healthcare Conferencebeing held inSan Francisco, CAonTuesday, January 14, 2025at4:30 p.m. Pacific Time.

To access the live webcast,click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website atwww.crinetics.com/events.

If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

ABOUTCRINETICS PHARMACEUTICALSCrinetics Pharmaceuticalsis a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@crinetics.com(858) 345-6340

Media:Natalie BadilloHead of Corporate Communicationsnbadillo@crinetics.com(858) 345-6075

Source: Crinetics Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com